DK0739355T3 - Kallikrein-inhiberende "Kunitz-domæne"-proteiner og analoger deraf - Google Patents

Kallikrein-inhiberende "Kunitz-domæne"-proteiner og analoger deraf

Info

Publication number
DK0739355T3
DK0739355T3 DK95909223T DK95909223T DK0739355T3 DK 0739355 T3 DK0739355 T3 DK 0739355T3 DK 95909223 T DK95909223 T DK 95909223T DK 95909223 T DK95909223 T DK 95909223T DK 0739355 T3 DK0739355 T3 DK 0739355T3
Authority
DK
Denmark
Prior art keywords
proteins
kallikrein
analogs
inhibiting
disclosed
Prior art date
Application number
DK95909223T
Other languages
English (en)
Inventor
Robert Charles Ladner
William Markland
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/208,264 external-priority patent/US6057287A/en
Application filed by Dyax Corp filed Critical Dyax Corp
Application granted granted Critical
Publication of DK0739355T3 publication Critical patent/DK0739355T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK95909223T 1994-01-11 1995-01-11 Kallikrein-inhiberende "Kunitz-domæne"-proteiner og analoger deraf DK0739355T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17996494A 1994-01-11 1994-01-11
US08/208,264 US6057287A (en) 1994-01-11 1994-03-10 Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PCT/US1995/000299 WO1995021601A2 (en) 1994-01-11 1995-01-11 Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof

Publications (1)

Publication Number Publication Date
DK0739355T3 true DK0739355T3 (da) 2005-01-24

Family

ID=26875859

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95909223T DK0739355T3 (da) 1994-01-11 1995-01-11 Kallikrein-inhiberende "Kunitz-domæne"-proteiner og analoger deraf

Country Status (10)

Country Link
US (3) US5795865A (da)
EP (1) EP0739355B1 (da)
JP (1) JP3805785B2 (da)
AT (1) ATE275583T1 (da)
CA (1) CA2180950C (da)
DE (1) DE69533472T2 (da)
DK (1) DK0739355T3 (da)
ES (1) ES2227545T3 (da)
PT (1) PT739355E (da)
WO (1) WO1995021601A2 (da)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291662B1 (en) * 1984-12-05 2001-09-18 Amgen Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences
PT737207E (pt) * 1994-01-11 2005-02-28 Dyax Corp Inibidores de plasmina humana derivados de dominios kunitz
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
JP3805785B2 (ja) * 1994-01-11 2006-08-09 ダイアックス コープ． カリクレイン阻害クニッツドメイン蛋白質およびその相同体
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
IL126115A (en) * 1996-03-11 2007-03-08 Aerovance Inc Significantly purified protein with suppressive activity for sirin protease and its pharmaceutical preparations
US5981471A (en) 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
US6946439B2 (en) 1997-02-06 2005-09-20 Entre Med, Inc. Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
US20060025329A1 (en) * 1997-02-06 2006-02-02 Todd Hembrough Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
WO1998051788A2 (en) * 1997-05-12 1998-11-19 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method and construct for inhibition of cell migration
DE19725014A1 (de) * 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
EP1082430A1 (en) * 1998-05-28 2001-03-14 ZymoGenetics, Inc. Kunitz domain polypeptide and materials and methods for making it
US6087473A (en) * 1999-05-26 2000-07-11 Zymogenetics, Inc. Kunitz domain polypeptide and materials and methods for making it
US6380354B1 (en) * 1998-09-03 2002-04-30 Zymogenetics, Inc. Kunitz domain polypeptide zkun6
AR030257A1 (es) * 1998-12-22 2003-08-20 Bayer Ag Uso de un inhibidor de proteasa serina de tipo kunitz para la fabricacion de un medicamento para acelerar la velocidad de aclaramiento mucociliar
US20070140979A1 (en) * 1998-12-22 2007-06-21 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
US6294648B1 (en) * 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity
WO2001046230A2 (en) * 1999-12-22 2001-06-28 Zymogenetics, Inc. Kunitz domain polypeptide zkun11
US6544760B2 (en) 1999-12-22 2003-04-08 Zymogenetics, Inc. Kunitz domain polypeptide Zkun11
WO2001047958A2 (en) * 1999-12-29 2001-07-05 Zymogenetics, Inc. Kunitz domain polypeptide zkun10
US20020004224A1 (en) * 2000-02-29 2002-01-10 Sheppard Paul O. Kunitz domain polypeptide zkun8
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
US20040054082A1 (en) * 2001-12-03 2004-03-18 Bank David H Toughened polymer blends with improved surface properties
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
EP2090589A1 (en) * 2002-02-07 2009-08-19 Dyax Corp. Albumin-fused Kunitz domain peptides
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
PT1941867E (pt) * 2002-06-07 2012-02-16 Dyax Corp Polipeptídeo contendo um domínio kunitz modificado
DK2386310T3 (da) 2002-08-28 2019-02-25 Dyax Corp Fremgangsmåder til at konservere organer og væv
ATE500345T1 (de) * 2003-01-07 2011-03-15 Dyax Corp Kunitz-domäne-bibliothek
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
CN1798838B (zh) 2003-04-04 2012-01-04 洛桑大学 一种蛋白酶的抑制剂蛋白及其用途
US20050089515A1 (en) * 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors
JP4775259B2 (ja) 2004-03-31 2011-09-21 味の素株式会社 アニリン誘導体
US7432238B2 (en) * 2004-04-16 2008-10-07 Stc.Unm Human Kunitz-type inhibitor with enhanced antifibrinolytic activity
AU2011218732B2 (en) * 2004-09-27 2013-07-04 Takeda Pharmaceutical Company Limited Kallikrein Inhibitors and Uses Thereof
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
AU2005309722B2 (en) * 2004-11-22 2011-10-20 Dyax Corp. Plasmin-inhibitory therapies
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
WO2007009069A2 (en) * 2005-07-13 2007-01-18 Amgen Mountain View Inc. Heat lysis production of proteins
US20080090760A2 (en) * 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
PL1981519T3 (pl) 2005-12-29 2018-07-31 Dyax Corp. Hamowanie proteaz
EP3088522B1 (en) * 2005-12-29 2017-11-29 The Regents of the University of California Methods and compositions related to mutant kunitz domain i of tfpi-2
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
WO2007106746A2 (en) * 2006-03-10 2007-09-20 Dyax Corp. Formulations for ecallantide
PL2374472T3 (pl) * 2006-03-16 2018-11-30 Dyax Corp. Kompozycje i sposoby leczenia zaburzeń okulistycznych
JP5337493B2 (ja) * 2006-03-16 2013-11-06 ダイアックス コーポレーション セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法
WO2008077478A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
WO2008091692A2 (en) * 2007-01-25 2008-07-31 Joslin Diabetes Center, Inc. Methods of diagnosing, treating, and preventing increased vascular permeability
EP2195010A4 (en) * 2007-08-21 2012-03-14 Genzyme Corp TREATMENT WITH INHIBITORS OF KALLIKREINE
EP2195011A4 (en) * 2007-08-23 2010-12-01 Genzyme Corp TREATMENT WITH CALLICINE INHIBITORS
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CA3021759A1 (en) 2010-01-06 2011-07-14 Dyax Corp. Plasma kallikrein binding proteins
US8816055B2 (en) 2011-01-06 2014-08-26 Dyax Corp. Plasma kallikrein binding proteins
WO2013172954A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc Peptide and peptidomimetic inhibitors
LT2946206T (lt) 2013-01-20 2019-04-25 Dyax Corp. Pkal sąlygotų sutrikimų vertinimas, tyrimas ir gydymas
CA2897336C (en) 2013-01-20 2023-10-17 Dyax Corp. Evaluation and treatment of pkal-mediated disorders
DK3060908T3 (da) 2013-10-21 2021-05-25 Dyax Corp Diagnosticering og behandling af autoimmune sygdomme
BR112016008970B1 (pt) 2013-10-21 2023-12-26 Takeda Pharmaceutical Company Limited Método de ativação ex vivo, método para avaliar ativação plasmática e ensaio ex vivo
PL3096798T3 (pl) 2014-01-21 2021-07-26 Takeda Pharmaceutical Company Limited Białka wiążące kalikreinę osocza i ich zastosowanie w leczeniu obrzęku naczynioruchowego
CN106459210A (zh) 2014-03-27 2017-02-22 戴埃克斯有限公司 用于治疗糖尿病黄斑性水肿的组合物和方法
BR112017020864A2 (pt) 2015-03-30 2018-07-10 Dyax Corp inibidores de calicreína plasmática e usos dos mesmos para a prevenção de ataque de angioedema hereditário
MX2018001786A (es) 2015-08-13 2018-06-06 Dyax Corp Tubos de extraccion de sangre segregada que contienen inhibidores de proteasa para la evaluacion de activacion del sistema de contacto.
MX2018004763A (es) 2015-10-19 2018-09-06 Dyax Corp Inmunoensayo para detectar quininogeno escindido de alto peso molecular.
CN116077648A (zh) 2015-12-11 2023-05-09 武田药品工业株式会社 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
KR20230044024A (ko) 2016-09-16 2023-03-31 다케다 파머수티컬 컴패니 리미티드 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커
WO2018053260A1 (en) 2016-09-16 2018-03-22 Dyax Corp. Rna biomarkers for hereditary angioedema
NZ751481A (en) 2016-09-16 2024-02-23 Takeda Pharmaceuticals Co Metabolite biomarkers for diseases associated with the contact activation system
HUP1700012A2 (en) 2017-01-06 2018-07-30 Evolveritas Kft Novel proteins and use thereof
MA53490A (fr) 2018-08-30 2022-05-04 Takeda Pharmaceuticals Co Inhibiteurs de la kallicréine plasmatique et leurs utilisations pour traiter une crise d'angio-odème héréditaire
US20200317815A1 (en) 2019-03-14 2020-10-08 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
AU2021209045A1 (en) 2020-01-13 2022-07-28 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
EP4126219A2 (en) 2020-04-04 2023-02-08 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response
WO2024003617A2 (en) 2022-06-30 2024-01-04 Takeda Pharmaceutical Company Limited Protein biomarkers for lanadelumab treatment
WO2024069200A2 (en) 2022-09-29 2024-04-04 Evolveritas Biotechnológiai Korlátolt Felelősségű Társaság A modified protein scaffold and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2619246A1 (de) * 1976-04-30 1977-11-10 Bayer Ag Desamino-derivate des kallikrein- trypsin-inhibitors, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
DE2654124A1 (de) * 1976-11-29 1978-06-01 Bayer Ag Derivate des trypsin-kallikrein-inhibitors aus rinderorganen (bpti) mit proteasenhemmwirkung und antiphlogistischer wirkung, ihre herstellung und ihre verwendung als arzneimittel
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) * 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) * 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4609725A (en) * 1984-10-09 1986-09-02 Merck & Co., Inc. Cardiac atrial peptides
EP0285123A3 (en) * 1987-04-03 1989-02-01 Stabra AG A method for complete mutagenesis of nucleic acids
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL104325A (en) * 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104324A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104326A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
JP3805785B2 (ja) * 1994-01-11 2006-08-09 ダイアックス コープ． カリクレイン阻害クニッツドメイン蛋白質およびその相同体

Also Published As

Publication number Publication date
US6333402B1 (en) 2001-12-25
ES2227545T3 (es) 2005-04-01
WO1995021601A2 (en) 1995-08-17
DE69533472T2 (de) 2006-01-12
JP3805785B2 (ja) 2006-08-09
US5795865A (en) 1998-08-18
CA2180950C (en) 2005-03-29
CA2180950A1 (en) 1995-08-17
EP0739355A1 (en) 1996-10-30
DE69533472D1 (de) 2004-10-14
EP0739355B1 (en) 2004-09-08
WO1995021601A3 (en) 1995-09-21
ATE275583T1 (de) 2004-09-15
US5994125A (en) 1999-11-30
JPH09511131A (ja) 1997-11-11
PT739355E (pt) 2005-01-31

Similar Documents

Publication Publication Date Title
DK0739355T3 (da) Kallikrein-inhiberende "Kunitz-domæne"-proteiner og analoger deraf
WO1995018830A3 (en) Inhibitors of human plasmin derived from the kunitz domains
EP1484339A3 (en) Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same
DK0535091T3 (da) Knogleinducerende farmaceutiske formuleringer
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
FI880464A0 (fi) Bekaempningsmedel mot tandplaque och -karies.
NO965098D0 (no) Perfluoralkylketoninhibitorer av elastase og fremgangsmåter for fremstilling av disse
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
IL81964A (en) Aprotinin and aprotinin homologues in which the amino acids in positions 15 and 52 have benn substituted
BR9811099A (pt) Inibidores de urocinase
SE9602263D0 (sv) New amino acid derivatives
NO983294L (no) Bowman-Birk inhibitor for hankj°nn dysfunksjon
DE69626671D1 (de) Fusionsproteine bestehend aus gewebefaktor-kunitzdomäne als inhibitoren des faktors viia
ES2167364T3 (es) Inhibidores de trombina.
GB9216558D0 (en) Modified proteases
ATE401337T1 (de) Antiangiogene polypeptide
DK0828483T3 (da) Anvendelse af tropolonderivater som inhibitorer af enzymet inositolmonophosphatase
IE890270L (en) Proteins derived from human alpha 2 plasmin inhibitor
UA9703A (uk) Антипротеіназний засіб
MY118194A (en) Pharmaceutical compositions for use in inhibiting bone resorption
GEP19991605B (en) Inhibitor, Its Obtaining and Use
ES2080657A1 (es) Proteasas modificadas.
UA32651C2 (uk) Спосіб напіввідкритої лапаростомії